Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A pioneering academic conference will bring together, for the first time, people from all over the world dealing with the problem of poor quality medicines and their impact on public health. The Medicine Quality & Public Health conference will take place at Keble College, Oxford, 23-28 Sept 2018. It will provide a unique opportunity for health authorities, scientists, pharmacists, lawyers and international organisations to discuss the problem and outline the necessary steps to tackle the issue on a global scale.

Pills

The proliferation of poor quality medicines is an important but neglected public health problem, threatening millions of people all over the world, both in developing and wealthy countries. Although – rightly - there has been much attention to improving access to affordable medicines, there has been less emphasis on ensuring that they are good quality or not altogether falsified.

“All over the world, medicines regulatory authorities, research groups, international organisations, law enforcement agencies and other key stakeholders, including the pharmaceutical industry, are working hard to keep patients safe and to try to ensure that the benefits of modern medicine are delivered,” says Prof Paul Newton, Head of the Medicine Quality Group at the Infectious Diseases Data Observatory (IDDO), Director of the Oxford clinical research unit in Laos and the instigator of the conference.

“However, there has never been an opportunity for the diverse stakeholders involved in medicine quality and drug regulation to come together within the framework of a dedicated academic conference to share ideas and expertise. One of the event’s key objectives is to develop a consensus statement to be widely disseminated to interested parties and policy makers, establishing the conference as a turning point in our collective approach to tackling poor quality medicines.”

The conference was inspired by a successful multidisciplinary annual course on the Quality of Medical Products & Public Health, which has been held since 2015 at the London School of Hygiene & Tropical Medicine and Boston University. This year the course and conference will run sequentially, allowing participants to combine in-depth training with networking and scientific discussion.

Discounts and fellowships are available for participants from low- and middle-income countries.

If you are interested in attending the conference tickets are nearly sold out, please visit the conference website or email mqph2018@ndm.ox.ac.uk.

Similar stories

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

RECOVERY Trial announced as overall winner of Best COVID-19 Response Project Award in the UK

The RECOVERY Trial has won the Project Management Institute’s Special Covid-19 UK Response Project Award. The award specifically recognised RECOVERY’s work to investigate whether the cheap steroid dexamethasone was an effective treatment for patients hospitalised with severe COVID-19.

ISARIC COVID-19 clinical database passes ½ million patient records mark

COVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

RECOVERY Trial named joint winner of HDR UK’s Impact of the Year Award

The RECOVERY trial has been jointly awarded Health Data Research UK’s 2021 Impact of the Year Award. This award is open to projects which had effectively used health data to improve people’s lives, including through clinical practice, policy, software, algorithms, or publications. The award was presented by James O’Shaughnessy at HDR UK’s online Annual Scientific Conference: Data Insights in a Pandemic.